Berberine inhibits breast carcinoma proliferation and metastasis under hypoxic microenvironment involving gut microbiota and endogenous metabolites

Sun, Yanfang; Zhou, Qianqian; Chen, Fang‐Ming; Gao, Xiaoyan; Yang, Linjun; Jin, Xiaoyan; Wink, Michaël; Sharopov, Farukh; Sethi, Gautam

doi:10.1016/j.phrs.2023.106817

Cited by 15 publications

(3 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 31 Herein, our data verified that BBR treatment might suppress breast cancer cell proliferation, invasion, migration, and induce apoptosis in vitro, in agreement with previous studies. 32 , 33 Consistently, the repression of BBR exposure on breast cancer growth has been validated in vivo. In total, the above findings demonstrated the anticancer activity of BBR in breast cancer.…”

Section: Discussionmentioning

confidence: 65%

Berberine inhibits the progression of breast cancer by regulating METTL3‐mediated m6A modification of FGF7 mRNA

Fu,

Liu,

Tong

2024

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundBerberine (BBR), an isoquinoline alkaloid from Coptidis rhizoma, has been found to have powerful activities against various human malignancies, including breast cancer. However, the underlying antitumor mechanisms of BBR in breast cancer remain poorly understood.MethodsBreast cancer cells were cultured and treated with different doses (0, 20, 40, and 60 μM) of BBR for 48 h. Cell viability, proliferation, apoptosis, invasion, and migration were assessed using 3‐(4, 5‐dimethyl‐2‐thiazolyl)‐2, 5‐diphenyl‐2H‐tetrazolium bromide (MTT), 5‐ethynyl‐2′‐deoxyuridine (EdU), flow cytometry, transwell, and wound healing assays. Fibroblast growth factor 7 (FGF7), methyltransferase‐like 3 (METTL3), and insulin‐like growth factor‐2 mRNA‐binding protein 3 (IGF2BP3) mRNA levels and protein levels were measured using real‐time quantitative polymerase chain reaction (RT‐qPCR) and western blot. Interaction between METTL3 and FGF7 m6A was assessed using methylated RNA immunoprecipitation (MeRIP)‐qPCR and RNA immunoprecipitation (RIP) assay. Binding ability between IGF2BP3 and FGF7 mRNA was analyzed using RIP assay.ResultsBBR treatment hindered breast cancer cell proliferation, invasion, migration, and induced apoptosis. FGF7 expression was upregulated in breast cancer tissues, while its level was reduced in BBR‐treated tumor cells. FGF7 upregulation relieved the repression of BBR on breast cancer cell malignant behaviors. In mechanism, METTL3 stabilized FGF7 mRNA through the m6A‐IGF2BP3‐dependent mechanism and naturally improved FGF7 expression. BBR treatment inhibited breast cancer growth in vivo.ConclusionBBR treatment blocked breast cancer cell growth and metastasis partly by regulating METTL3‐mediated m6A modification of FGF7 mRNA, providing a promising therapeutic target for breast cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 65%

Berberine inhibits the progression of breast cancer by regulating METTL3‐mediated m6A modification of FGF7 mRNA

Fu,

Liu,

Tong

2024

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…6 Therefore, identifying a new drug with few side effects and a strong curative effect has become an urgent need for tumor treatment. In recent years, a large number of natural products derived from plants, such as terpenoids, 7 polyphenols, 8 alkaloids, 9 and flavonoids, 10 have attracted increased amounts of attention due to their potential antitumor potential. Among these flavonoids, baicalein (BE) has anti-inflammatory, 11 antioxidant, 12 and antitumor effects.…”

Section: Introductionmentioning

confidence: 99%

Preparation of Biomimetic Selenium–Baicalein Nanoparticles and Their Targeted Therapeutic Application in Nonsmall Cell Lung Cancer

Shi,

Wang,

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

In this study, we prepared bionic selenium–baicalein nanoparticles (ACM-SSe–BE) for the targeted treatment of nonsmall cell lung cancer. Due to the coating of the A549 membrane, the system has homologous targeting capabilities, allowing for the preparation of target tumor cells. The borate ester bond between selenium nanoparticles (SSe) and baicalein (BE) is pH-sensitive and can break under acidic conditions in the tumor microenvironment to achieve the targeted release of BE at the tumor site. Moreover, SSe further enhances the antitumor effect of BE by increasing the production of ROS in tumor cells. Transmission electron microscopy (TEM) images and dynamic light scattering (DLS) showed that the ACM-SSe–BE had a particle size of approximately 155 ± 2 nm. FTIR verified the successful coupling of SSe and BE. In vitro release experiments indicated that the cumulative release of ACM-SSe–BE at pH 5.5 after 24 h was 69.39 ± 1.07%, which was less than the 20% release at pH 7.4, confirming the pH-sensitive release of BE in ACM-SSe–BE. Cell uptake experiments and in vivo imaging showed that ACM-SSe–BE had good targeting ability. The results of MTT, flow cytometry, Western blot, and cell immunofluorescence staining demonstrated that ACM-SSe–BE promoted A549 cell apoptosis and inhibited cell proliferation. The in vivo antitumor results were consistent with those of the cell experiments. These results clearly suggested that ACM-SSe–BE will be a promising bionic nanosystem for the treatment of nonsmall cell lung cancer.

show abstract

“…For example, the Kushen injection has been demonstrated to show a significant anti-tumor effect in non-small cell lung cancer, gastric cancer, breast cancer, and colorectal cancer (Li, Niu, et al, 2023). Berberine was reported to suppress breast cancer cell growth and metastasis under a hypoxic microenvironment, which provides a candidate herb for breast cancer treatment (Sun et al, 2023). The combination of different herbs, especially herbs that possess similar pharmacological activities, is commonly applied in the clinic.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic study of the interaction between luteolin and magnoflorine in rats

Liu,

2023

Chem Biol Drug Des

View full text Add to dashboard Cite

Both luteolin and magnoflorine have been reported to regulate the development of breast cancer, which makes them easier to co‐administrate. Luteolin was co‐administrated with magnoflorine to evaluate their potential interaction. The pharmacokinetic study was performed on male Sprague–Dawley rats randomly grouped as the single administration of luteolin and the co‐administration of luteolin and magnoflorine with six rats of each. CaCO‐2 cell transwell assay was employed for transport evaluation, and the metabolic stability of luteolin and CYP3A activity were assessed in rat liver microsomes. The effect of luteolin on MDA‐MB‐231 cells was assessed with CCK8 assay. Magnoflorine significantly changed the pharmacokinetic profile of luteolin with increased area under the curve (AUC), prolonged t1/2, and reduced clearance rate. Magnoflorine also suppressed the efflux ratio and improved the in vitro metabolic stability of luteolin. Magnoflorine also enhanced the inhibitory effect of luteolin on MDA‐MB‐231 cells. Magnoflorine significantly inhibited CYP3A activity with the IC50 of 18.99 μM. Magnoflorine prolonged the system exposure, enhanced the metabolic stability, and enhanced the anti‐tumor effect of luteolin through inactivating CYP3A.

show abstract

Berberine inhibits breast carcinoma proliferation and metastasis under hypoxic microenvironment involving gut microbiota and endogenous metabolites

Cited by 15 publications

References 65 publications

Berberine inhibits the progression of breast cancer by regulating METTL3‐mediated m6A modification of FGF7 mRNA

Berberine inhibits the progression of breast cancer by regulating METTL3‐mediated m6A modification of FGF7 mRNA

Preparation of Biomimetic Selenium–Baicalein Nanoparticles and Their Targeted Therapeutic Application in Nonsmall Cell Lung Cancer

Pharmacokinetic study of the interaction between luteolin and magnoflorine in rats

Contact Info

Product

Resources

About